India Pharma Outlook Team | Wednesday, 03 June 2026
Pharmaceutical major Lupin Limited and its alliance partner Natco Pharma Limited have received approval from the United States Food and Drug Administration (FDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials. The approval covers Natco’s Abbreviated New Drug Application (ANDA) for the product, which is bioequivalent to Halaven Injection, the reference listed drug marketed by Eisai Inc.
The approval allows the companies to market the generic version in the United States, providing an alternative treatment option for patients requiring advanced oncology therapies. Generic approvals continue to play an important role in improving access to medicines while supporting healthcare affordability.
Eribulin Mesylate Injection is indicated for adults with metastatic breast cancer who have previously received at least two chemotherapy regimens for metastatic disease. It is also approved for patients with unresectable or metastatic liposarcoma who have undergone prior anthracycline-containing treatment.
Breast cancer remains one of the most commonly diagnosed cancers worldwide, while liposarcoma is a rare form of soft tissue cancer. Access to effective treatment options is critical for patients with advanced-stage disease, particularly when earlier therapies have not produced the desired outcomes.
Also Read: A Cure for Postpartum Depression - If You Can Afford It
The FDA approval expands the availability of oncology medicines designed to address these challenging conditions and supports continued growth in the generic cancer treatment segment.
According to IQVIA's Moving Annual Total data for April 2026, Halaven Injection recorded estimated annual sales of approximately USD 43.7 million in the United States. The approval provides Lupin and Natco with an opportunity to enter an established oncology market and expand their presence in specialty pharmaceuticals.
The development also highlights the growing contribution of Indian pharmaceutical companies in supplying complex generic medicines to regulated international markets. Oncology remains a key focus area due to rising cancer cases and increasing demand for cost-effective therapies.
Also Read: AI-Augmented Clinical Trials & Drug Development Evolution in India
In India, the oncology drugs market is estimated to be valued at around USD 2.2 billion and is expected to witness sustained growth driven by increasing cancer incidence, improved diagnosis rates, and broader access to treatment. As pharmaceutical companies continue to invest in oncology research and manufacturing capabilities, the segment is expected to remain a significant growth driver for the industry.
The latest approval further strengthens the oncology portfolios of both Lupin and Natco while reinforcing India's position as a major supplier of affordable generic medicines worldwide.
.jpg)
